ID   NPM_HUMAN               Reviewed;         294 AA.
AC   P06748; A8K3N7; B5BU00; D3DQL6; P08693; Q12826; Q13440; Q13441; Q14115;
AC   Q5EU94; Q5EU95; Q5EU96; Q5EU97; Q5EU98; Q5EU99; Q6V962; Q8WTW5; Q96AT6;
AC   Q96DC4; Q96EA5; Q9BYG9; Q9UDJ7;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 2.
DT   28-JAN-2026, entry version 271.
DE   RecName: Full=Nucleophosmin;
DE            Short=NPM;
DE   AltName: Full=Nucleolar phosphoprotein B23;
DE   AltName: Full=Nucleolar protein NO38;
DE   AltName: Full=Numatrin;
GN   Name=NPM1 {ECO:0000312|HGNC:HGNC:7910}; Synonyms=NPM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2713355; DOI=10.1021/bi00429a017;
RA   Chan W.-Y., Liu Q.R., Borjigin J., Busch H., Rennert O.M., Tease L.A.,
RA   Chan P.-K.;
RT   "Characterization of the cDNA encoding human nucleophosmin and studies of
RT   its role in normal and abnormal growth.";
RL   Biochemistry 28:1033-1039(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=B-cell lymphoma;
RX   PubMed=2775293; DOI=10.1016/0006-291x(89)92100-1;
RA   Li X., McNeilage L.J., Whittingham S.;
RT   "The nucleotide sequence of a human cDNA encoding the highly conserved
RT   nucleolar phosphoprotein B23.";
RL   Biochem. Biophys. Res. Commun. 163:72-78(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Amnion;
RX   PubMed=2478125; DOI=10.1016/0006-291x(89)91699-9;
RA   Zhang X.T., Thomis D.C., Samuel C.E.;
RT   "Isolation and characterization of a molecular cDNA clone of a human mRNA
RT   from interferon-treated cells encoding nucleolar protein B23, numatrin.";
RL   Biochem. Biophys. Res. Commun. 164:176-184(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=9092633; DOI=10.1093/nar/25.6.1225;
RA   Chan P.-K., Chan F.Y., Morris S.W., Xie Z.;
RT   "Isolation and characterization of the human nucleophosmin/B23 (NPM) gene:
RT   identification of the YY1 binding site at the 5' enhancer region.";
RL   Nucleic Acids Res. 25:1225-1232(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Okuwaki M., Nagata K.;
RT   "Human homologue of Rat B23.2.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN ACUTE MYELOGENOUS LEUKEMIA.
RC   TISSUE=Bone marrow;
RX   PubMed=15659725; DOI=10.1056/nejmoa041974;
RA   Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L.,
RA   La Starza R., Diverio D., Colombo E., Santucci A., Bigerna B., Pacini R.,
RA   Pucciarini A., Liso A., Vignetti M., Fazi P., Meani N., Pettirossi V.,
RA   Saglio G., Mandelli F., Lo-Coco F., Pelicci P.-G., Martelli M.F.;
RT   "Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal
RT   karyotype.";
RL   N. Engl. J. Med. 352:254-266(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=16574551; DOI=10.1016/s1470-2045(06)70661-1;
RA   Bolli N., Galimberti S., Martelli M.P., Tabarrini A., Roti G., Mecucci C.,
RA   Martelli M.F., Petrini M., Falini B.;
RT   "Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after
RT   diagnosis of acute myeloid leukaemia.";
RL   Lancet Oncol. 7:350-352(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RA   Lu L., Huang X.Y., Yin L.L., Xu M., Li J.M., Zhou Z.M., Sha J.H.;
RT   "Cloning of a new transcript of nucleophosmin in testis.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Bone marrow, Brain, Kidney, Lung, Prostate, Testis, and Urinary
RC   bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-133, AND CHROMOSOMAL TRANSLOCATION WITH
RP   RARA.
RC   TISSUE=Bone marrow;
RX   PubMed=8562957;
RA   Redner R.L., Rush E.A., Faas S., Rudert W.A., Corey S.J.;
RT   "The t(5;17) variant of acute promyelocytic leukemia expresses a
RT   nucleophosmin-retinoic acid receptor fusion.";
RL   Blood 87:882-886(1996).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-117, AND CHROMOSOMAL TRANSLOCATION WITH
RP   ALK.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=8122112; DOI=10.1126/science.8122112;
RA   Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N.,
RA   Saltman D.L., Look A.T.;
RT   "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-
RT   Hodgkin's lymphoma.";
RL   Science 263:1281-1284(1994).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-117, AND CHROMOSOMAL TRANSLOCATION WITH
RP   ALK.
RC   TISSUE=Lymphoma;
RX   PubMed=8633037; DOI=10.1073/pnas.93.9.4181;
RA   Fujimoto J., Shiota M., Iwahara T., Seki N., Satoh H., Mori S.,
RA   Yamamoto T.;
RT   "Characterization of the transforming activity of p80, a
RT   hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal
RT   translocation t(2;5).";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4181-4186(1996).
RN   [17]
RP   PROTEIN SEQUENCE OF 1-24; 33-101; 104-141; 240-248 AND 278-291, ACETYLATION
RP   AT MET-1, PHOSPHORYLATION AT SER-125, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-294 (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2602120;
RA   Hale T.K., Mansfield B.C.;
RT   "Nucleotide sequence of a cDNA clone representing a third allele of human
RT   protein B23.";
RL   Nucleic Acids Res. 17:10112-10112(1989).
RN   [19]
RP   PROTEIN SEQUENCE OF 33-54.
RC   TISSUE=Colon carcinoma;
RX   PubMed=9150948; DOI=10.1002/elps.1150180344;
RA   Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
RT   "A two-dimensional gel database of human colon carcinoma proteins.";
RL   Electrophoresis 18:605-613(1997).
RN   [20]
RP   PROTEIN SEQUENCE OF 34-42; 50-67; 137-151; 218-227; 252-266 AND 277-286
RP   (ISOFORM 1), AND INTERACTION WITH HTLV1 REX PROTEIN (MICROBIAL INFECTION).
RX   PubMed=8314759; DOI=10.1016/s0021-9258(19)85191-8;
RA   Adachi Y., Copeland T.D., Hatanaka M., Oroszlan S.;
RT   "Nucleolar targeting signal of Rex protein of human T-cell leukemia virus
RT   type I specifically binds to nucleolar shuttle protein B-23.";
RL   J. Biol. Chem. 268:13930-13934(1993).
RN   [21]
RP   PROTEIN SEQUENCE OF 33-42; 213-221; 251-257 AND 268-274, FUNCTION,
RP   INTERACTION WITH EIF2AK2, AND PHOSPHORYLATION.
RX   PubMed=12882984; DOI=10.1074/jbc.m301392200;
RA   Pang Q., Christianson T.A., Koretsky T., Carlson H., David L., Keeble W.,
RA   Faulkner G.R., Speckhart A., Bagby G.C.;
RT   "Nucleophosmin interacts with and inhibits the catalytic function of
RT   eukaryotic initiation factor 2 kinase PKR.";
RL   J. Biol. Chem. 278:41709-41717(2003).
RN   [22]
RP   PROTEIN SEQUENCE OF 115-134.
RX   PubMed=3944116; DOI=10.1016/s0021-9258(17)36022-2;
RA   Chan P.-K., Aldrich M.B., Cook R.G., Busch H.;
RT   "Amino acid sequence of protein B23 phosphorylation site.";
RL   J. Biol. Chem. 261:1868-1872(1986).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 213-294 (ISOFORM 1), AND PROTEIN SEQUENCE OF
RP   227-294.
RX   PubMed=2429957; DOI=10.1016/s0021-9258(18)67023-1;
RA   Chan P.-K., Chan W.-Y., Yung B.Y.M., Cook R.G., Aldrich M.B., Ku D.,
RA   Goldknopf I.L., Busch H.;
RT   "Amino acid sequence of a specific antigenic peptide of protein B23.";
RL   J. Biol. Chem. 261:14335-14341(1986).
RN   [24]
RP   INTERACTION WITH NOP2.
RX   PubMed=8089149; DOI=10.1016/s0021-9258(17)31583-1;
RA   Valdez B.C., Perlaky L., Henning D., Saijo Y., Chan P.K., Busch H.;
RT   "Identification of the nuclear and nucleolar localization signals of the
RT   protein p120. Interaction with translocation protein B23.";
RL   J. Biol. Chem. 269:23776-23783(1994).
RN   [25]
RP   ADP-RIBOSYLATION.
RX   PubMed=7631008; DOI=10.2307/3579152;
RA   Ramsamooj P., Notario V., Dritschilo A.;
RT   "Modification of nucleolar protein B23 after exposure to ionizing
RT   radiation.";
RL   Radiat. Res. 143:158-164(1995).
RN   [26]
RP   CHROMOSOMAL TRANSLOCATION WITH MLF1.
RX   PubMed=8570204;
RA   Yoneda-Kato N., Look A.T., Kirstein M.N., Valentine M.B., Raimondi S.C.,
RA   Cohen K.J., Carroll A.J., Morris S.W.;
RT   "The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid
RT   leukemia produces a novel fusion gene, NPM-MLF1.";
RL   Oncogene 12:265-275(1996).
RN   [27]
RP   PHOSPHORYLATION BY CDK2.
RX   PubMed=11051553; DOI=10.1016/s0092-8674(00)00093-3;
RA   Okuda M., Horn H.F., Tarapore P., Tokuyama Y., Smulian A.G., Chan P.K.,
RA   Knudsen E.S., Hofmann I.A., Snyder J.D., Bove K.E., Fukasawa K.;
RT   "Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome
RT   duplication.";
RL   Cell 103:127-140(2000).
RN   [28]
RP   INTERACTION WITH HEPATITIS DELTA VIRUS S-HDAG (MICROBIAL INFECTION).
RX   PubMed=11309377; DOI=10.1074/jbc.m010087200;
RA   Huang W.H., Yung B.Y., Syu W.J., Lee Y.H.;
RT   "The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens
RT   and modulates the hepatitis delta virus RNA replication.";
RL   J. Biol. Chem. 276:25166-25175(2001).
RN   [29]
RP   PHOSPHORYLATION AT THR-199; THR-219 AND THR-237, AND MUTAGENESIS OF
RP   THR-199; THR-219; THR-234 AND THR-237.
RX   PubMed=12058066; DOI=10.1091/mbc.02-03-0036;
RA   Okuwaki M., Tsujimoto M., Nagata K.;
RT   "The RNA binding activity of a ribosome biogenesis factor,
RT   nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-
RT   dependent kinase and by association with its subtype.";
RL   Mol. Biol. Cell 13:2016-2030(2002).
RN   [30]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [31]
RP   REVIEW.
RX   PubMed=12214246; DOI=10.1038/sj.onc.1205708;
RA   Okuda M.;
RT   "The role of nucleophosmin in centrosome duplication.";
RL   Oncogene 21:6170-6174(2002).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND SUBCELLULAR LOCATION [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [33]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION, AND INTERACTION WITH NEK2.
RX   PubMed=15388344; DOI=10.1016/j.febslet.2004.08.047;
RA   Yao J., Fu C., Ding X., Guo Z., Zenreski A., Chen Y., Ahmed K., Liao J.,
RA   Dou Z., Yao X.;
RT   "Nek2A kinase regulates the localization of numatrin to centrosome in
RT   mitosis.";
RL   FEBS Lett. 575:112-118(2004).
RN   [34]
RP   PHOSPHORYLATION AT SER-4 BY PLK1.
RX   PubMed=15190079; DOI=10.1074/jbc.m403264200;
RA   Zhang H., Shi X., Paddon H., Hampong M., Dai W., Pelech S.;
RT   "B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of
RT   polo-like kinase 1.";
RL   J. Biol. Chem. 279:35726-35734(2004).
RN   [35]
RP   INTERACTION WITH RPGR.
RX   PubMed=15772089; DOI=10.1093/hmg/ddi129;
RA   Shu X., Fry A.M., Tulloch B., Manson F.D., Crabb J.W., Khanna H.,
RA   Faragher A.J., Lennon A., He S., Trojan P., Giessl A., Wolfrum U.,
RA   Vervoort R., Swaroop A., Wright A.F.;
RT   "RPGR ORF15 isoform co-localizes with RPGRIP1 at centrioles and basal
RT   bodies and interacts with nucleophosmin.";
RL   Hum. Mol. Genet. 14:1183-1197(2005).
RN   [36]
RP   ACETYLATION AT LYS-212; LYS-229; LYS-230; LYS-250; LYS-257 AND LYS-292, AND
RP   FUNCTION AS A CHAPERONE.
RX   PubMed=16107701; DOI=10.1128/mcb.25.17.7534-7545.2005;
RA   Swaminathan V., Kishore A.H., Febitha K.K., Kundu T.K.;
RT   "Human histone chaperone nucleophosmin enhances acetylation-dependent
RT   chromatin transcription.";
RL   Mol. Cell. Biol. 25:7534-7545(2005).
RN   [37]
RP   SUMOYLATION AT LYS-230 AND LYS-263.
RX   PubMed=15897463; DOI=10.1073/pnas.0502978102;
RA   Tago K., Chiocca S., Sherr C.J.;
RT   "Sumoylation induced by the Arf tumor suppressor: a p53-independent
RT   function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:7689-7694(2005).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND THR-95, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-150; LYS-154 AND LYS-212, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16916647; DOI=10.1016/j.molcel.2006.06.026;
RA   Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y.,
RA   Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
RT   "Substrate and functional diversity of lysine acetylation revealed by a
RT   proteomics survey.";
RL   Mol. Cell 23:607-618(2006).
RN   [40]
RP   FUNCTION, AND INTERACTION WITH ROCK2.
RX   PubMed=17015463; DOI=10.1128/mcb.01383-06;
RA   Ma Z., Kanai M., Kawamura K., Kaibuchi K., Ye K., Fukasawa K.;
RT   "Interaction between ROCK II and nucleophosmin/B23 in the regulation of
RT   centrosome duplication.";
RL   Mol. Cell. Biol. 26:9016-9034(2006).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; THR-199 AND SER-254, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [42]
RP   INTERACTION WITH NSUN2.
RX   PubMed=17215513; DOI=10.1091/mbc.e06-11-1021;
RA   Sakita-Suto S., Kanda A., Suzuki F., Sato S., Takata T., Tatsuka M.;
RT   "Aurora-B regulates RNA methyltransferase NSUN2.";
RL   Mol. Biol. Cell 18:1107-1117(2007).
RN   [43]
RP   INTERACTION WITH SENP3, AND MUTAGENESIS OF LYS-263.
RX   PubMed=18259216; DOI=10.1038/embor.2008.3;
RA   Haindl M., Harasim T., Eick D., Muller S.;
RT   "The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of
RT   nucleophosmin and is required for rRNA processing.";
RL   EMBO Rep. 9:273-279(2008).
RN   [44]
RP   INTERACTION WITH SENP3, AND SUBCELLULAR LOCATION.
RX   PubMed=19015314; DOI=10.1083/jcb.200807185;
RA   Yun C., Wang Y., Mukhopadhyay D., Backlund P., Kolli N., Yergey A.,
RA   Wilkinson K.D., Dasso M.;
RT   "Nucleolar protein B23/nucleophosmin regulates the vertebrate SUMO pathway
RT   through SENP3 and SENP5 proteases.";
RL   J. Cell Biol. 183:589-595(2008).
RN   [45]
RP   REVIEW.
RX   PubMed=18024471; DOI=10.1093/jb/mvm222;
RA   Okuwaki M.;
RT   "The structure and functions of NPM1/Nucleophosmin/B23, a multifunctional
RT   nucleolar acidic protein.";
RL   J. Biochem. 143:441-448(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-125 AND THR-279, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-125, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [48]
RP   FUNCTION.
RX   PubMed=18809582; DOI=10.1128/mcb.01548-07;
RA   Maggi L.B. Jr., Kuchenruether M., Dadey D.Y., Schwope R.M., Grisendi S.,
RA   Townsend R.R., Pandolfi P.P., Weber J.D.;
RT   "Nucleophosmin serves as a rate-limiting nuclear export chaperone for the
RT   Mammalian ribosome.";
RL   Mol. Cell. Biol. 28:7050-7065(2008).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; THR-75; THR-95; SER-125;
RP   SER-139; THR-234; THR-237 AND SER-243, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [51]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [52]
RP   INTERACTION WITH RRP1B.
RX   PubMed=19710015; DOI=10.1074/jbc.m109.023457;
RA   Crawford N.P., Yang H., Mattaini K.R., Hunter K.W.;
RT   "The metastasis efficiency modifier ribosomal RNA processing 1 homolog B
RT   (RRP1B) is a chromatin-associated factor.";
RL   J. Biol. Chem. 284:28660-28673(2009).
RN   [53]
RP   SUBCELLULAR LOCATION, UBIQUITINATION, AND DEUBIQUITINATION BY USP36.
RX   PubMed=19208757; DOI=10.1242/jcs.044461;
RA   Endo A., Matsumoto M., Inada T., Yamamoto A., Nakayama K.I., Kitamura N.,
RA   Komada M.;
RT   "Nucleolar structure and function are regulated by the deubiquitylating
RT   enzyme USP36.";
RL   J. Cell Sci. 122:678-686(2009).
RN   [54]
RP   FUNCTION, INTERACTION WITH APEX1, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19188445; DOI=10.1128/mcb.01337-08;
RA   Vascotto C., Fantini D., Romanello M., Cesaratto L., Deganuto M.,
RA   Leonardi A., Radicella J.P., Kelley M.R., D'Ambrosio C., Scaloni A.,
RA   Quadrifoglio F., Tell G.;
RT   "APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the
RT   rRNA quality control process.";
RL   Mol. Cell. Biol. 29:1834-1854(2009).
RN   [55]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-125, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [57]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-150; LYS-257; LYS-267 AND
RP   LYS-273, ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-257 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [58]
RP   INTERACTION WITH CEBPA.
RX   PubMed=20075868; DOI=10.1038/emboj.2009.404;
RA   Muller C., Bremer A., Schreiber S., Eichwald S., Calkhoven C.F.;
RT   "Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA
RT   transcription and cell size.";
RL   EMBO J. 29:897-909(2010).
RN   [59]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RPS10.
RX   PubMed=20159986; DOI=10.1074/jbc.m110.103911;
RA   Ren J., Wang Y., Liang Y., Zhang Y., Bao S., Xu Z.;
RT   "Methylation of ribosomal protein S10 by protein-arginine methyltransferase
RT   5 regulates ribosome biogenesis.";
RL   J. Biol. Chem. 285:12695-12705(2010).
RN   [60]
RP   INTERACTION WITH RRP1B.
RX   PubMed=20926688; DOI=10.1091/mbc.e10-04-0287;
RA   Chamousset D., De Wever V., Moorhead G.B., Chen Y., Boisvert F.M.,
RA   Lamond A.I., Trinkle-Mulcahy L.;
RT   "RRP1B targets PP1 to mammalian cell nucleoli and is associated with pre-
RT   60S ribosomal subunits.";
RL   Mol. Biol. Cell 21:4212-4226(2010).
RN   [61]
RP   FUNCTION, PHOSPHORYLATION AT SER-4 BY PLK2, AND MUTAGENESIS OF SER-4;
RP   THR-95; SER-125 AND THR-199.
RX   PubMed=20352051; DOI=10.1371/journal.pone.0009849;
RA   Krause A., Hoffmann I.;
RT   "Polo-like kinase 2-dependent phosphorylation of NPM/B23 on serine 4
RT   triggers centriole duplication.";
RL   PLoS ONE 5:E9849-E9849(2010).
RN   [62]
RP   PHOSPHORYLATION AT THR-199 BY CDK6.
RX   PubMed=20333249; DOI=10.1371/journal.ppat.1000818;
RA   Sarek G., Jaerviluoma A., Moore H.M., Tojkander S., Vartia S.,
RA   Biberfeld P., Laiho M., Ojala P.M.;
RT   "Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.";
RL   PLoS Pathog. 6:E1000818-E1000818(2010).
RN   [63]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-4; SER-10; SER-70; THR-95; SER-125; SER-137; SER-139;
RP   THR-199; SER-242; SER-243; SER-260 AND THR-279, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-254 (ISOFORM 3), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [64]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [65]
RP   FUNCTION, AND INTERACTION WITH BRCA2.
RX   PubMed=21084279; DOI=10.1158/0008-5472.can-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form a
RT   complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [66]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CENPW.
RX   PubMed=22002061; DOI=10.1074/jbc.m111.228411;
RA   Chun Y., Park B., Koh W., Lee S., Cheon Y., Kim R., Che L., Lee S.;
RT   "New centromeric component CENP-W is an RNA-associated nuclear matrix
RT   protein that interacts with nucleophosmin/B23 protein.";
RL   J. Biol. Chem. 286:42758-42769(2011).
RN   [67]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-4; SER-70; SER-125; SER-227; SER-243 AND SER-254, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [68]
RP   FUNCTION, INTERACTION WITH ATF5, AND SUBCELLULAR LOCATION.
RX   PubMed=22528486; DOI=10.1074/jbc.m112.363622;
RA   Liu X., Liu D., Qian D., Dai J., An Y., Jiang S., Stanley B., Yang J.,
RA   Wang B., Liu X., Liu D.X.;
RT   "Nucleophosmin (NPM1/B23) interacts with activating transcription factor 5
RT   (ATF5) protein and promotes proteasome- and caspase-dependent ATF5
RT   degradation in hepatocellular carcinoma cells.";
RL   J. Biol. Chem. 287:19599-19609(2012).
RN   [69]
RP   INTERACTION WITH DDX31.
RX   PubMed=23019224; DOI=10.1158/0008-5472.can-12-1645;
RA   Fukawa T., Ono M., Matsuo T., Uehara H., Miki T., Nakamura Y.,
RA   Kanayama H.O., Katagiri T.;
RT   "DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through
RT   its interaction with NPM1 in renal cell carcinomas.";
RL   Cancer Res. 72:5867-5877(2012).
RN   [70]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [71]
RP   INTERACTION WITH NPM3.
RX   PubMed=22362753; DOI=10.1093/nar/gks162;
RA   Okuwaki M., Sumi A., Hisaoka M., Saotome-Nakamura A., Akashi S.,
RA   Nishimura Y., Nagata K.;
RT   "Function of homo- and hetero-oligomers of human
RT   nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during
RT   sperm chromatin remodeling.";
RL   Nucleic Acids Res. 40:4861-4878(2012).
RN   [72]
RP   INTERACTION WITH ALKBH2.
RX   PubMed=23972994; DOI=10.1016/j.celrep.2013.07.027;
RA   Li P., Gao S., Wang L., Yu F., Li J., Wang C., Li J., Wong J.;
RT   "ABH2 couples regulation of ribosomal DNA transcription with DNA alkylation
RT   repair.";
RL   Cell Rep. 4:817-829(2013).
RN   [73]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4; SER-10; SER-43; SER-70;
RP   THR-95; SER-125; SER-139; THR-234; THR-237; SER-242; SER-243; SER-254 AND
RP   SER-260, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [74]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70 AND SER-243, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [75]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-27; LYS-32; LYS-248 AND LYS-250,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [76]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-248; LYS-257 AND LYS-267,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [77]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MYC AND NOP53.
RX   PubMed=25956029; DOI=10.1016/j.ajpath.2015.03.016;
RA   Kim J.Y., Cho Y.E., Park J.H.;
RT   "The nucleolar protein GLTSCR2 is an upstream negative regulator of the
RT   oncogenic Nucleophosmin-MYC axis.";
RL   Am. J. Pathol. 185:2061-2068(2015).
RN   [78]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32 AND LYS-215, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [79]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=25818168; DOI=10.1111/jcmm.12474;
RA   Kim J.Y., Cho Y.E., An Y.M., Kim S.H., Lee Y.G., Park J.H., Lee S.;
RT   "GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical
RT   cancer.";
RL   J. Cell. Mol. Med. 19:1245-1252(2015).
RN   [80]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [81]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [82]
RP   ADP-RIBOSYLATION AT SER-207.
RX   PubMed=28190768; DOI=10.1016/j.molcel.2017.01.003;
RA   Bonfiglio J.J., Fontana P., Zhang Q., Colby T., Gibbs-Seymour I.,
RA   Atanassov I., Bartlett E., Zaja R., Ahel I., Matic I.;
RT   "Serine ADP-ribosylation depends on HPF1.";
RL   Mol. Cell 0:0-0(2017).
RN   [83]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-141; LYS-150; LYS-215;
RP   LYS-248; LYS-250; LYS-257; LYS-263; LYS-267 AND LYS-273, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [84]
RP   INTERACTION WITH ARID3C, AND SUBCELLULAR LOCATION.
RX   PubMed=38231884; DOI=10.1021/acs.jproteome.3c00509;
RA   Kim H.S., Kim Y.I., Cho J.Y.;
RT   "ARID3C Acts as a Regulator of Monocyte-to-Macrophage Differentiation
RT   Interacting with NPM1.";
RL   J. Proteome Res. 0:0-0(2024).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 9-124.
RX   PubMed=17879352; DOI=10.1002/prot.21504;
RA   Lee H.H., Kim H.S., Kang J.Y., Lee B.I., Ha J.Y., Yoon H.J., Lim S.O.,
RA   Jung G., Suh S.W.;
RT   "Crystal structure of human nucleophosmin-core reveals plasticity of the
RT   pentamer-pentamer interface.";
RL   Proteins 69:672-678(2007).
RN   [86]
RP   STRUCTURE BY NMR OF 243-294, AND MUTAGENESIS OF LYS-248; LYS-250; LYS-267;
RP   PHE-268; PHE-276; TRP-288 AND TRP-290.
RX   PubMed=18511415; DOI=10.1074/jbc.m801706200;
RA   Grummitt C.G., Townsley F.M., Johnson C.M., Warren A.J., Bycroft M.;
RT   "Structural consequences of nucleophosmin mutations in acute myeloid
RT   leukemia.";
RL   J. Biol. Chem. 283:23326-23332(2008).
CC   -!- FUNCTION: Involved in diverse cellular processes such as ribosome
CC       biogenesis, centrosome duplication, protein chaperoning, histone
CC       assembly, cell proliferation, and regulation of tumor suppressors
CC       p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear
CC       export. Associated with nucleolar ribonucleoprotein structures and bind
CC       single-stranded nucleic acids. Acts as a chaperonin for the core
CC       histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on
CC       apurinic/apyrimidinic (AP) double-stranded DNA but inhibits APEX1
CC       endonuclease activity on AP single-stranded RNA. May exert a control of
CC       APEX1 endonuclease activity within nucleoli devoted to repair AP on
CC       rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2,
CC       regulates centrosome duplication. Regulates centriole duplication:
CC       phosphorylation by PLK2 is able to trigger centriole replication.
CC       Negatively regulates the activation of EIF2AK2/PKR and suppresses
CC       apoptosis through inhibition of EIF2AK2/PKR autophosphorylation.
CC       Antagonizes the inhibitory effect of ATF5 on cell proliferation and
CC       relieves ATF5-induced G2/M blockade (PubMed:22528486). In complex with
CC       MYC enhances the transcription of MYC target genes (PubMed:25956029).
CC       May act as chaperonin or cotransporter in the nucleolar localization of
CC       transcription termination factor TTF1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61937, ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:16107701, ECO:0000269|PubMed:17015463,
CC       ECO:0000269|PubMed:18809582, ECO:0000269|PubMed:19188445,
CC       ECO:0000269|PubMed:20352051, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:22002061, ECO:0000269|PubMed:22528486,
CC       ECO:0000269|PubMed:25956029}.
CC   -!- SUBUNIT: Decamer formed by two pentameric rings associated in a head-
CC       to-head fashion (By similarity). Disulfide-linked dimers under certain
CC       conditions (PubMed:25818168). The SWAP complex consists of NPM1, NCL,
CC       PARP1 and SWAP70 (By similarity). Interacts with NSUN2 and SENP3.
CC       Interacts with the methylated form of RPS10. Interacts (via N-terminal
CC       domain) with APEX1; the interaction is RNA-dependent and decreases in
CC       hydrogen peroxide-damaged cells. Interacts with isoform 1 of NEK2.
CC       Interacts with ROCK2 and BRCA2. Interacts with RPGR. Interacts with
CC       CENPW. Interacts with EIF2AK2/PKR. Interacts with CEBPA (isoform 4)
CC       (PubMed:20075868). Interacts with DDX31; this interaction prevents
CC       interaction between NPM1 and HDM2 (PubMed:23019224). Interacts with
CC       MYC; competitive with NOP53 (PubMed:25956029). Interacts with NOP53;
CC       the interaction is direct and competitive with MYC (PubMed:25956029).
CC       Interacts with LRRC34 (By similarity). Interacts with RRP1B
CC       (PubMed:19710015, PubMed:20926688). Interacts with NPM3
CC       (PubMed:22362753). Interacts with ALKBH2 (PubMed:23972994). Interacts
CC       with TTF1 (via C-terminal region) (By similarity). Interacts with NOP2
CC       (PubMed:8089149). Interacts with ARID3C (via REKLES DOMAIN); the
CC       interaction mediates ARID3C nuclear shuttling (PubMed:38231884).
CC       {ECO:0000250|UniProtKB:Q61937, ECO:0000269|PubMed:12882984,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:15772089,
CC       ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:17215513,
CC       ECO:0000269|PubMed:18259216, ECO:0000269|PubMed:19015314,
CC       ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:19710015,
CC       ECO:0000269|PubMed:20075868, ECO:0000269|PubMed:20159986,
CC       ECO:0000269|PubMed:20926688, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:22002061, ECO:0000269|PubMed:22362753,
CC       ECO:0000269|PubMed:22528486, ECO:0000269|PubMed:23019224,
CC       ECO:0000269|PubMed:23972994, ECO:0000269|PubMed:25818168,
CC       ECO:0000269|PubMed:25956029, ECO:0000269|PubMed:38231884,
CC       ECO:0000269|PubMed:8089149}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with hepatitis delta virus S-
CC       HDAg. {ECO:0000269|PubMed:11309377}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HTLV1 Rex protein (via N-
CC       terminal nuclear localization signal). {ECO:0000269|PubMed:8314759}.
CC   -!- INTERACTION:
CC       P06748; O14965: AURKA; NbExp=3; IntAct=EBI-78579, EBI-448680;
CC       P06748; Q96GD4: AURKB; NbExp=6; IntAct=EBI-78579, EBI-624291;
CC       P06748; Q96CT7: CCDC124; NbExp=8; IntAct=EBI-78579, EBI-5461329;
CC       P06748; Q8N726: CDKN2A; NbExp=2; IntAct=EBI-78579, EBI-625922;
CC       P06748; Q96MT8: CEP63; NbExp=2; IntAct=EBI-78579, EBI-741977;
CC       P06748; P10176: COX8A; NbExp=3; IntAct=EBI-78579, EBI-3904738;
CC       P06748; Q10570: CPSF1; NbExp=2; IntAct=EBI-78579, EBI-347859;
CC       P06748; P19525: EIF2AK2; NbExp=4; IntAct=EBI-78579, EBI-640775;
CC       P06748; P60228: EIF3E; NbExp=3; IntAct=EBI-78579, EBI-347740;
CC       P06748; Q13547: HDAC1; NbExp=2; IntAct=EBI-78579, EBI-301834;
CC       P06748; Q92769: HDAC2; NbExp=2; IntAct=EBI-78579, EBI-301821;
CC       P06748; Q9BXL5: HEMGN; NbExp=7; IntAct=EBI-78579, EBI-3916399;
CC       P06748; Q92876: KLK6; NbExp=3; IntAct=EBI-78579, EBI-2432309;
CC       P06748; O00505: KPNA3; NbExp=2; IntAct=EBI-78579, EBI-358297;
CC       P06748; O00629: KPNA4; NbExp=2; IntAct=EBI-78579, EBI-396343;
CC       P06748; Q71RC2: LARP4; NbExp=3; IntAct=EBI-78579, EBI-2878091;
CC       P06748; Q9NX58: LYAR; NbExp=2; IntAct=EBI-78579, EBI-713507;
CC       P06748; Q00987: MDM2; NbExp=5; IntAct=EBI-78579, EBI-389668;
CC       P06748; Q9BZQ8: NIBAN1; NbExp=7; IntAct=EBI-78579, EBI-6916466;
CC       P06748; Q86SE8: NPM2; NbExp=8; IntAct=EBI-78579, EBI-6658150;
CC       P06748; Q86SE8-2: NPM2; NbExp=5; IntAct=EBI-78579, EBI-12193061;
CC       P06748; Q8IZL8: PELP1; NbExp=4; IntAct=EBI-78579, EBI-716449;
CC       P06748; Q96BK5: PINX1; NbExp=13; IntAct=EBI-78579, EBI-721782;
CC       P06748; P49207: RPL34; NbExp=2; IntAct=EBI-78579, EBI-1051893;
CC       P06748; P62753: RPS6; NbExp=3; IntAct=EBI-78579, EBI-356625;
CC       P06748; Q9H4L4: SENP3; NbExp=7; IntAct=EBI-78579, EBI-2880236;
CC       P06748; O14746: TERT; NbExp=5; IntAct=EBI-78579, EBI-1772203;
CC       P06748; P05549: TFAP2A; NbExp=6; IntAct=EBI-78579, EBI-347351;
CC       P06748; P04637: TP53; NbExp=6; IntAct=EBI-78579, EBI-366083;
CC       P06748; P63104: YWHAZ; NbExp=2; IntAct=EBI-78579, EBI-347088;
CC       P06748; Q64364: Cdkn2a; Xeno; NbExp=2; IntAct=EBI-78579, EBI-1202287;
CC       P06748; P24938: L2; Xeno; NbExp=4; IntAct=EBI-78579, EBI-7481199;
CC       P06748; P68951: L2; Xeno; NbExp=5; IntAct=EBI-78579, EBI-7481182;
CC       P06748; P0DOE7: M; Xeno; NbExp=3; IntAct=EBI-78579, EBI-10042882;
CC       P06748; Q6UPD4: NP; Xeno; NbExp=4; IntAct=EBI-78579, EBI-25616456;
CC       P06748; P03427: PB2; Xeno; NbExp=3; IntAct=EBI-78579, EBI-8430745;
CC       P06748; B1Q2W9: pre-C/C; Xeno; NbExp=8; IntAct=EBI-78579, EBI-9081051;
CC       P06748; Q98147; Xeno; NbExp=2; IntAct=EBI-78579, EBI-626601;
CC       P06748-1; P49450-1: CENPA; NbExp=3; IntAct=EBI-354150, EBI-15826012;
CC       P06748-1; P63165: SUMO1; NbExp=3; IntAct=EBI-354150, EBI-80140;
CC       P06748-1; P04637: TP53; NbExp=3; IntAct=EBI-354150, EBI-366083;
CC       P06748-1; Q14669: TRIP12; NbExp=2; IntAct=EBI-354150, EBI-308443;
CC       P06748-2; Q86SE8-2: NPM2; NbExp=4; IntAct=EBI-354154, EBI-12193061;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:19208757,
CC       ECO:0000269|PubMed:22528486, ECO:0000269|PubMed:25818168,
CC       ECO:0000269|PubMed:25956029}. Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:25818168}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:14654843}.
CC       Note=Generally nucleolar, but is translocated to the nucleoplasm in
CC       case of serum starvation or treatment with anticancer drugs. Has been
CC       found in the cytoplasm in patients with primary acute myelogenous
CC       leukemia (AML), but not with secondary AML. Co-localizes with the
CC       methylated form of RPS10 in the granular component (GC) region of the
CC       nucleolus. Colocalized with nucleolin and APEX1 in nucleoli. Isoform 1
CC       of NEK2 is required for its localization to the centrosome during
CC       mitosis. Can shuttle between cytoplasm and nucleus (PubMed:38231884).
CC       {ECO:0000269|PubMed:38231884}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P06748-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P06748-2; Sequence=VSP_003616;
CC       Name=3;
CC         IsoId=P06748-3; Sequence=VSP_043599;
CC   -!- PTM: Acetylated at C-terminal lysine residues, thereby increasing
CC       affinity to histones. {ECO:0000269|PubMed:16107701,
CC       ECO:0000269|Ref.17}.
CC   -!- PTM: ADP-ribosylated.
CC   -!- PTM: Phosphorylated at Ser-4 by PLK1 and PLK2. Phosphorylation at Ser-4
CC       by PLK2 in S phase is required for centriole duplication and is
CC       sufficient to trigger centriole replication. Phosphorylation at Ser-4
CC       by PLK1 takes place during mitosis. Phosphorylated by CDK2 at Ser-125
CC       and Thr-199. Phosphorylation at Thr-199 may trigger initiation of
CC       centrosome duplication. Phosphorylated by CDK1 at Thr-199, Thr-219,
CC       Thr-234 and Thr-237 during cell mitosis. When these four sites are
CC       phosphorylated, RNA-binding activity seem to be abolished. May be
CC       phosphorylated at Ser-70 by NEK2. The Thr-199 phosphorylated form has
CC       higher affinity for ROCK2. CDK6 triggers Thr-199 phosphorylation when
CC       complexed to Kaposi's sarcoma herpesvirus (KSHV) V-cyclin, leading to
CC       viral reactivation by reducing viral LANA levels.
CC       {ECO:0000269|PubMed:11051553, ECO:0000269|PubMed:12058066,
CC       ECO:0000269|PubMed:12882984, ECO:0000269|PubMed:15190079,
CC       ECO:0000269|PubMed:15388344, ECO:0000269|PubMed:20333249,
CC       ECO:0000269|PubMed:20352051, ECO:0000269|Ref.17}.
CC   -!- PTM: Sumoylated by ARF. {ECO:0000269|PubMed:15897463}.
CC   -!- PTM: Ubiquitinated. Ubiquitination leads to proteasomal degradation.
CC       Deubiquitinated by USP36 (PubMed:19208757).
CC       {ECO:0000269|PubMed:19208757, ECO:0000269|PubMed:25818168}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is found in a
CC       form of non-Hodgkin lymphoma. Translocation t(2;5)(p23;q35) with ALK.
CC       The resulting chimeric NPM1-ALK protein homodimerize and the kinase
CC       becomes constitutively activated. {ECO:0000269|PubMed:8122112,
CC       ECO:0000269|PubMed:8633037}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is found in a
CC       form of acute promyelocytic leukemia. Translocation t(5;17)(q32;q11)
CC       with RARA. {ECO:0000269|PubMed:8562957}.
CC   -!- DISEASE: Note=A chromosomal aberration involving NPM1 is a cause of
CC       myelodysplastic syndrome (MDS). Translocation t(3;5)(q25.1;q34) with
CC       MLF1. {ECO:0000269|PubMed:8570204}.
CC   -!- DISEASE: Note=Defects in NPM1 are associated with acute myelogenous
CC       leukemia (AML). Mutations in exon 12 affecting the C-terminus of the
CC       protein are associated with an aberrant cytoplasmic location.
CC       {ECO:0000269|PubMed:15659725}.
CC   -!- SIMILARITY: Belongs to the nucleoplasmin family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/22/NPM1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23613; AAA36380.1; -; mRNA.
DR   EMBL; M28699; AAA58386.1; -; mRNA.
DR   EMBL; M26697; AAA36385.1; -; mRNA.
DR   EMBL; U89321; AAB94739.1; -; Genomic_DNA.
DR   EMBL; U89309; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89310; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89311; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89313; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89314; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89317; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; U89319; AAB94739.1; JOINED; Genomic_DNA.
DR   EMBL; AB042278; BAB40600.1; -; mRNA.
DR   EMBL; AY740634; AAW67752.1; -; mRNA.
DR   EMBL; AY740635; AAW67753.1; -; mRNA.
DR   EMBL; AY740636; AAW67754.1; -; mRNA.
DR   EMBL; AY740637; AAW67755.1; -; mRNA.
DR   EMBL; AY740638; AAW67756.1; -; mRNA.
DR   EMBL; AY740639; AAW67757.1; -; mRNA.
DR   EMBL; AY740640; AAW67758.1; -; mRNA.
DR   EMBL; DQ303464; ABC40399.1; -; mRNA.
DR   EMBL; AY347529; AAQ24860.1; -; mRNA.
DR   EMBL; BT007011; AAP35657.1; -; mRNA.
DR   EMBL; AK290652; BAF83341.1; -; mRNA.
DR   EMBL; AB451236; BAG70050.1; -; mRNA.
DR   EMBL; AB451361; BAG70175.1; -; mRNA.
DR   EMBL; CH471062; EAW61443.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61446.1; -; Genomic_DNA.
DR   EMBL; BC002398; AAH02398.1; -; mRNA.
DR   EMBL; BC008495; AAH08495.1; -; mRNA.
DR   EMBL; BC009623; AAH09623.1; -; mRNA.
DR   EMBL; BC012566; AAH12566.1; -; mRNA.
DR   EMBL; BC014349; AAH14349.1; -; mRNA.
DR   EMBL; BC016716; AAH16716.1; -; mRNA.
DR   EMBL; BC016768; AAH16768.1; -; mRNA.
DR   EMBL; BC016824; AAH16824.1; -; mRNA.
DR   EMBL; BC021668; AAH21668.1; -; mRNA.
DR   EMBL; BC021983; AAH21983.1; -; mRNA.
DR   EMBL; BC050628; AAH50628.1; -; mRNA.
DR   EMBL; BC107754; AAI07755.1; -; mRNA.
DR   EMBL; U41742; AAB00112.1; ALT_TERM; mRNA.
DR   EMBL; U41743; AAB00113.1; ALT_TERM; mRNA.
DR   EMBL; U04946; AAA58698.1; ALT_TERM; mRNA.
DR   EMBL; D45915; BAA08343.1; ALT_TERM; mRNA.
DR   EMBL; X16934; CAA34809.1; -; mRNA.
DR   EMBL; J02590; AAA36473.1; -; mRNA.
DR   EMBL; M31004; AAA36474.1; -; mRNA.
DR   CCDS; CCDS43399.1; -. [P06748-3]
DR   CCDS; CCDS4376.1; -. [P06748-1]
DR   CCDS; CCDS4377.1; -. [P06748-2]
DR   PIR; A33423; A32915.
DR   PIR; I38491; I38491.
DR   RefSeq; NP_001032827.1; NM_001037738.3. [P06748-3]
DR   RefSeq; NP_001341935.1; NM_001355006.2. [P06748-1]
DR   RefSeq; NP_002511.1; NM_002520.7. [P06748-1]
DR   RefSeq; NP_954654.1; NM_199185.4. [P06748-2]
DR   PDB; 2LLH; NMR; -; A=225-294.
DR   PDB; 2P1B; X-ray; 2.75 A; A/B/C/D/E/F/G/H/I/J=9-122.
DR   PDB; 2VXD; NMR; -; A=243-294.
DR   PDB; 5EHD; X-ray; 2.55 A; A/B/C/D/E/F/G/H/I/J/a/b/c/d/e/f/g/h/i/j=9-124.
DR   PDB; 7OBG; X-ray; 1.80 A; B=284-294.
DR   PDB; 7OBH; X-ray; 2.00 A; B=284-294.
DR   PDB; 8AH2; X-ray; 2.90 A; A/C=44-55.
DR   PDB; 8AS5; EM; 2.50 A; A/B/C/D/E=1-294.
DR   PDBsum; 2LLH; -.
DR   PDBsum; 2P1B; -.
DR   PDBsum; 2VXD; -.
DR   PDBsum; 5EHD; -.
DR   PDBsum; 7OBG; -.
DR   PDBsum; 7OBH; -.
DR   PDBsum; 8AH2; -.
DR   PDBsum; 8AS5; -.
DR   AlphaFoldDB; P06748; -.
DR   BMRB; P06748; -.
DR   EMDB; EMD-15606; -.
DR   SMR; P06748; -.
DR   BioGRID; 110929; 1283.
DR   CORUM; P06748; -.
DR   DIP; DIP-30932N; -.
DR   FunCoup; P06748; 1923.
DR   IntAct; P06748; 1134.
DR   MINT; P06748; -.
DR   STRING; 9606.ENSP00000296930; -.
DR   BindingDB; P06748; -.
DR   ChEMBL; CHEMBL5178; -.
DR   DrugBank; DB11638; Artenimol.
DR   DrugCentral; P06748; -.
DR   GlyCosmos; P06748; 4 sites, 1 glycan.
DR   GlyGen; P06748; 8 sites, 1 O-linked glycan (8 sites).
DR   iPTMnet; P06748; -.
DR   MetOSite; P06748; -.
DR   PhosphoSitePlus; P06748; -.
DR   SwissPalm; P06748; -.
DR   BioMuta; NPM1; -.
DR   DMDM; 114762; -.
DR   REPRODUCTION-2DPAGE; IPI00549248; -.
DR   jPOST; P06748; -.
DR   MassIVE; P06748; -.
DR   PaxDb; 9606-ENSP00000296930; -.
DR   PeptideAtlas; P06748; -.
DR   PRIDE; P06748; -.
DR   ProteomicsDB; 51927; -. [P06748-1]
DR   ProteomicsDB; 51928; -. [P06748-2]
DR   ProteomicsDB; 51929; -. [P06748-3]
DR   Pumba; P06748; -.
DR   TopDownProteomics; P06748-1; -. [P06748-1]
DR   TopDownProteomics; P06748-2; -. [P06748-2]
DR   TopDownProteomics; P06748-3; -. [P06748-3]
DR   Antibodypedia; 1828; 1350 antibodies from 48 providers.
DR   DNASU; 4869; -.
DR   Ensembl; ENST00000296930.10; ENSP00000296930.5; ENSG00000181163.15. [P06748-1]
DR   Ensembl; ENST00000351986.10; ENSP00000341168.6; ENSG00000181163.15. [P06748-2]
DR   Ensembl; ENST00000393820.2; ENSP00000377408.2; ENSG00000181163.15. [P06748-3]
DR   Ensembl; ENST00000517671.5; ENSP00000428755.1; ENSG00000181163.15. [P06748-1]
DR   Ensembl; ENST00000678280.1; ENSP00000503235.1; ENSG00000181163.15. [P06748-3]
DR   GeneID; 4869; -.
DR   KEGG; hsa:4869; -.
DR   MANE-Select; ENST00000296930.10; ENSP00000296930.5; NM_002520.7; NP_002511.1.
DR   UCSC; uc003mbh.4; human. [P06748-1]
DR   AGR; HGNC:7910; -.
DR   CIViC; 4869; 1 clinical assertion and 37 evidence items across 4 molecular profiles.
DR   ClinPGx; PA31712; -.
DR   CTD; 4869; -.
DR   DisGeNET; 4869; -.
DR   GeneCards; NPM1; -.
DR   HGNC; HGNC:7910; NPM1.
DR   HPA; ENSG00000181163; Low tissue specificity.
DR   MalaCards; NPM1; -.
DR   MIM; 164040; gene.
DR   OpenTargets; ENSG00000181163; -.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 98833; Acute myeloblastic leukemia without maturation.
DR   Orphanet; 402026; Acute myeloid leukemia with NPM1 somatic mutations.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 1775; Dyskeratosis congenita.
DR   Orphanet; 98842; Lymphomatoid papulosis.
DR   Orphanet; 300865; Primary cutaneous anaplastic large cell lymphoma.
DR   VEuPathDB; HostDB:ENSG00000181163; -.
DR   eggNOG; KOG0488; Eukaryota.
DR   GeneTree; ENSGT00940000153052; -.
DR   HOGENOM; CLU_058838_0_0_1; -.
DR   InParanoid; P06748; -.
DR   OMA; MEKGMNL; -.
DR   OrthoDB; 9946910at2759; -.
DR   PAN-GO; P06748; 16 GO annotations based on evolutionary models.
DR   PhylomeDB; P06748; -.
DR   PathwayCommons; P06748; -.
DR   Reactome; R-HSA-180746; Nuclear import of Rev protein.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-606279; Deposition of new CENPA-containing nucleosomes at the centromere.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-8869496; TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation.
DR   Reactome; R-HSA-9692914; SARS-CoV-1-host interactions.
DR   Reactome; R-HSA-9700645; ALK mutants bind TKIs.
DR   Reactome; R-HSA-9725370; Signaling by ALK fusions and activated point mutants.
DR   Reactome; R-HSA-9725371; Nuclear events stimulated by ALK signaling in cancer.
DR   Reactome; R-HSA-9833482; PKR-mediated signaling.
DR   SignaLink; P06748; -.
DR   SIGNOR; P06748; -.
DR   Agora; ENSG00000181163; -.
DR   BioGRID-ORCS; 4869; 540 hits in 1103 CRISPR screens.
DR   CD-CODE; 6AB35885; Synthetic Condensate 000052.
DR   CD-CODE; 71F78BB1; Synthetic Condensate 000049.
DR   CD-CODE; 80B4651A; Granular component.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; 9E412E21; Synthetic Condensate 000044.
DR   CD-CODE; A3AA02E8; Synthetic Condensate 000061.
DR   CD-CODE; CBF57B02; Synthetic Condensate 000043.
DR   CD-CODE; D551D4B1; Synthetic Condensate 000051.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; NPM1; human.
DR   EvolutionaryTrace; P06748; -.
DR   GeneWiki; NPM1; -.
DR   GenomeRNAi; 4869; -.
DR   Pharos; P06748; Tbio.
DR   PRO; PR:P06748; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P06748; protein.
DR   Bgee; ENSG00000181163; Expressed in calcaneal tendon and 191 other cell types or tissues.
DR   ExpressionAtlas; P06748; baseline and differential.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0001652; C:granular component; TAS:Reactome.
DR   GO; GO:0015934; C:large ribosomal subunit; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:CAFA.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:MGI.
DR   GO; GO:0015935; C:small ribosomal subunit; IEA:Ensembl.
DR   GO; GO:0031616; C:spindle pole centrosome; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:CAFA.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:UniProt.
DR   GO; GO:0051059; F:NF-kappaB binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0043023; F:ribosomal large subunit binding; IDA:MGI.
DR   GO; GO:0043024; F:ribosomal small subunit binding; IDA:MGI.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0019843; F:rRNA binding; IPI:DisProt.
DR   GO; GO:0030957; F:Tat protein binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0006884; P:cell volume homeostasis; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IDA:CAFA.
DR   GO; GO:0090398; P:cellular senescence; IMP:GO_Central.
DR   GO; GO:0007098; P:centrosome cycle; IMP:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; IDA:UniProtKB.
DR   GO; GO:0008104; P:intracellular protein localization; IDA:UniProtKB.
DR   GO; GO:0006886; P:intracellular protein transport; TAS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; IDA:UniProt.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0010826; P:negative regulation of centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0048025; P:negative regulation of mRNA splicing, via spliceosome; IEA:Ensembl.
DR   GO; GO:0044387; P:negative regulation of protein kinase activity by regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IDA:UniProtKB.
DR   GO; GO:1902751; P:positive regulation of cell cycle G2/M phase transition; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0010825; P:positive regulation of centrosome duplication; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:CAFA.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0006606; P:protein import into nucleus; IDA:UniProt.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0046599; P:regulation of centriole replication; IMP:UniProtKB.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IBA:GO_Central.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0060735; P:regulation of eIF2 alpha phosphorylation by dsRNA; IDA:UniProtKB.
DR   GO; GO:1902629; P:regulation of mRNA stability involved in cellular response to UV; IMP:UniProtKB.
DR   GO; GO:0042273; P:ribosomal large subunit biogenesis; IBA:GO_Central.
DR   GO; GO:0000055; P:ribosomal large subunit export from nucleus; IBA:GO_Central.
DR   GO; GO:0042274; P:ribosomal small subunit biogenesis; IBA:GO_Central.
DR   GO; GO:0000056; P:ribosomal small subunit export from nucleus; IBA:GO_Central.
DR   GO; GO:0042255; P:ribosome assembly; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   DisProt; DP01474; -.
DR   FunFam; 1.10.10.2100:FF:000001; Nucleophosmin 1; 1.
DR   FunFam; 2.60.120.340:FF:000001; Nucleophosmin 1; 1.
DR   Gene3D; 1.10.10.2100; -; 1.
DR   Gene3D; 2.60.120.340; Nucleoplasmin core domain; 1.
DR   IDEAL; IID00295; -.
DR   InterPro; IPR032569; NPM1_C.
DR   InterPro; IPR004301; Nucleoplasmin.
DR   InterPro; IPR024057; Nucleoplasmin_core_dom.
DR   InterPro; IPR036824; Nucleoplasmin_core_dom_sf.
DR   PANTHER; PTHR22747:SF28; NUCLEOPHOSMIN; 1.
DR   PANTHER; PTHR22747; NUCLEOPLASMIN; 1.
DR   Pfam; PF16276; NPM1-C; 1.
DR   Pfam; PF03066; Nucleoplasmin; 1.
DR   SUPFAM; SSF69203; Nucleoplasmin-like core domain; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Chaperone; Chromosomal rearrangement; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disulfide bond; Host-virus interaction;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Proteomics identification;
KW   Proto-oncogene; Reference proteome; RNA-binding; Ubl conjugation.
FT   CHAIN           1..294
FT                   /note="Nucleophosmin"
FT                   /id="PRO_0000219481"
FT   REGION          1..186
FT                   /note="Required for interaction with SENP3"
FT   REGION          1..117
FT                   /note="Necessary for interaction with APEX1"
FT                   /evidence="ECO:0000269|PubMed:19188445"
FT   REGION          120..247
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          187..215
FT                   /note="Interaction with NOP2"
FT                   /evidence="ECO:0000269|PubMed:8089149"
FT   REGION          243..294
FT                   /note="Required for nucleolar localization"
FT   MOTIF           152..157
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   MOTIF           191..197
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        120..132
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        161..187
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        188..200
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        202..222
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        223..235
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            55
FT                   /note="Interaction between pentamers"
FT                   /evidence="ECO:0000250"
FT   SITE            80
FT                   /note="Interaction between pentamers"
FT                   /evidence="ECO:0000250"
FT   SITE            175..176
FT                   /note="Breakpoint for translocation to form NPM1-MLF1"
FT                   /evidence="ECO:0000269|PubMed:8570204"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|Ref.17, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:22223895"
FT   MOD_RES         4
FT                   /note="Phosphoserine; by PLK1 and PLK2"
FT                   /evidence="ECO:0000269|PubMed:15190079,
FT                   ECO:0000269|PubMed:20352051, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         32
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         43
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         67
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61937"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         75
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         95
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         125
FT                   /note="Phosphoserine; by CDK2"
FT                   /evidence="ECO:0000269|Ref.17, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         137
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         150
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:16916647,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         154
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:16916647"
FT   MOD_RES         199
FT                   /note="Phosphothreonine; by CDK1, CDK2 and CDK6"
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0000269|PubMed:20333249, ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         207
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000269|PubMed:28190768"
FT   MOD_RES         212
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701,
FT                   ECO:0007744|PubMed:16916647"
FT   MOD_RES         219
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000305|PubMed:12058066"
FT   MOD_RES         227
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         229
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         230
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         234
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         237
FT                   /note="Phosphothreonine; by CDK1"
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         242
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         250
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   MOD_RES         254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         257
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:16107701,
FT                   ECO:0007744|PubMed:19608861"
FT   MOD_RES         260
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         267
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         267
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q61937"
FT   MOD_RES         273
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         279
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         292
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:16107701"
FT   CROSSLNK        27
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        141
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        150
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        215
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        230
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        248
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        248
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        250
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        257
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        257
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:15897463"
FT   CROSSLNK        263
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        267
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        267
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        273
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         195..223
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_003616"
FT   VAR_SEQ         258..294
FT                   /note="GGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL -> AH (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.5"
FT                   /id="VSP_043599"
FT   MUTAGEN         4
FT                   /note="S->A: Abolishes phosphorylation by PLK2 and impairs
FT                   centriole duplication."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         4
FT                   /note="S->D,E: Mimicks phosphorylation state, inducing
FT                   accumulation of centrioles."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         95
FT                   /note="T->A: Does not affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         125
FT                   /note="S->A: Does not affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:20352051"
FT   MUTAGEN         199
FT                   /note="T->A: Partial loss of phosphorylation. Does not
FT                   affect phosphorylation by PLK2."
FT                   /evidence="ECO:0000269|PubMed:12058066,
FT                   ECO:0000269|PubMed:20352051"
FT   MUTAGEN         219
FT                   /note="T->A: Partial loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         234
FT                   /note="T->A: Partial loss of phosphorylation; when
FT                   associated with A-237."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         237
FT                   /note="T->A: Partial loss of phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:12058066"
FT   MUTAGEN         248
FT                   /note="K->A: Partial destabilization of the structure."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         250
FT                   /note="K->A: Increase in the stabilization of the
FT                   structure."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         263
FT                   /note="K->A: Increase in the stabilization of the structure
FT                   and partial delocalization to the nucleoplasm. Complete
FT                   delocalization to the nucleoplasm; when associated with
FT                   A-267."
FT                   /evidence="ECO:0000269|PubMed:18259216"
FT   MUTAGEN         263
FT                   /note="K->R: No change in the sumoylation level."
FT                   /evidence="ECO:0000269|PubMed:18259216"
FT   MUTAGEN         267
FT                   /note="K->A: Increase in the stabilization of the structure
FT                   and complete delocalization to the nucleoplasm. Complete
FT                   delocalization to the nucleoplasm; when associated with
FT                   A-263."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         268
FT                   /note="F->A: Complete destabilization of the structure and
FT                   loss of nucleolus localization; when associated with
FT                   A-276."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         276
FT                   /note="F->A: Complete destabilization of the structure and
FT                   loss of nucleolus localization; when associated with
FT                   A-268."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         288
FT                   /note="W->A: Complete destabilization of the structure;
FT                   when associated with A-290."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   MUTAGEN         290
FT                   /note="W->A: Partial destabilization of the structure.
FT                   Complete destabilization of the structure; when associated
FT                   with A-288."
FT                   /evidence="ECO:0000269|PubMed:18511415"
FT   CONFLICT        80
FT                   /note="K -> E (in Ref. 13; AAH21983)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        129
FT                   /note="E -> D (in Ref. 22; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        168
FT                   /note="Missing (in Ref. 6; AAW67758)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        178
FT                   /note="D -> G (in Ref. 13; AAH16768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        183
FT                   /note="D -> N (in Ref. 11; BAG70175/BAG70050)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        213
FT                   /note="D -> P (in Ref. 23; AAA36473/AAA36474)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        214
FT                   /note="S -> L (in Ref. 21; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="P -> S (in Ref. 23; AAA36473)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        219..221
FT                   /note="TPR -> SSS (in Ref. 23; AAA36473)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        231
FT                   /note="Q -> R (in Ref. 8; AAQ24860)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        271
FT                   /note="Y -> C (in Ref. 13; AAH16768)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        287
FT                   /note="L -> F (in Ref. 13; AAH12566)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CLAVEEVSLRK (in Ref. 6;
FT                   AAW67752/AAW67755)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CMAVEEVSLRK (in Ref. 6; AAW67753 and 7;
FT                   ABC40399)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288..294
FT                   /note="WQWRKSL -> CVAVEEVSLRK (in Ref. 6; AAW67754)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290..294
FT                   /note="WRKSL -> SLAQVSLRK (in Ref. 6; AAW67756)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290..294
FT                   /note="WRKSL -> SLEKVSLRK (in Ref. 6; AAW67757)"
FT                   /evidence="ECO:0000305"
FT   STRAND          15..24
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          29..31
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          40..49
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          58..65
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          71..80
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          84..94
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          96..104
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   STRAND          109..117
FT                   /evidence="ECO:0007829|PDB:5EHD"
FT   HELIX           244..257
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   HELIX           265..275
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   HELIX           281..292
FT                   /evidence="ECO:0007829|PDB:2LLH"
FT   MOD_RES         P06748-3:254
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         P06748-3:257
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
SQ   SEQUENCE   294 AA;  32575 MW;  620BC7BA2E4A0054 CRC64;
     MEDSMDMDMS PLRPQNYLFG CELKADKDYH FKVDNDENEH QLSLRTVSLG AGAKDELHIV
     EAEAMNYEGS PIKVTLATLK MSVQPTVSLG GFEITPPVVL RLKCGSGPVH ISGQHLVAVE
     EDAESEDEEE EDVKLLSISG KRSAPGGGSK VPQKKVKLAA DEDDDDDDEE DDDEDDDDDD
     FDDEEAEEKA PVKKSIRDTP AKNAQKSNQN GKDSKPSSTP RSKGQESFKK QEKTPKTPKG
     PSSVEDIKAK MQASIEKGGS LPKVEAKFIN YVKNCFRMTD QEAIQDLWQW RKSL
//
